Enterprise Value

212.5M

Cash

297.7M

Avg Qtr Burn

-27.03M

Short % of Float

7.31%

Insider Ownership

14.72%

Institutional Own.

36.20%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

Naporafenib (pan-RAF inhibitor) w/ trametinib Details
Solid tumor/s, RAS Q61X solid tumors

Phase 1b

Data readout

ERAS-007 w/ encorafenib and cetuximab Details
Cancer, Advanced malignancies, Gastrointestinal stromal tumors, Colorectal cancer , BRAFm Colorectal Cancer

Phase 1b

Data readout

Phase 1

Data readout

ERAS-007 + ERAS-601 Details
Solid tumor/s, Cancer

Failed

Discontinued

ERAS-601 (SHP2 inhibitor) Details
Solid tumor/s, Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued

ERAS-007 Details
Non-small cell lung carcinoma

Failed

Discontinued